Nima Farzan

Kinnate Biopharma Inc.

Nima Farzan brings over two decades of executive leadership experience in the biopharma industry to the Kinnate Biopharma Inc. team. Prior to joining Kinnate Biopharma, Farzan spent seven years at PaxVax, where he was most recently president and CEO. While there, he successfully led a team of 250 people through a number of commercial product launches and negotiated the sale of PaxVax to Emergent BioSolutions in 2018. Prior to PaxVax, he was at Novartis AG in a series of roles of increasing responsibility, most recently as vice president of U.S. marketing at Novartis’ Vaccines and Diagnostics division. Prior to Novartis, Farzan worked at DoubleTwist, a pioneering genomics company, and was a consultant with Boston Consulting Group. He was a member of the founding board of the Coalition for Epidemic Preparedness Innovations (CEPI). He is on the executive committee of the Northern California Chapter of Young President’s Organization (YPO) and a trustee at the Hamlin School. He is also a director of Keros Therapeutics (NASDAQ: KROS). He holds a bachelor’s degree in human biology from Stanford University and a Master of Business Administration degree from the Harvard Business School.